COX-2 inhibition synergizes with radioimmunotherapy by promoting TCF1⁺CD8⁺ T cell infiltration in NSCLC

References

1. 1.↵
   2. Thai AA,
   3. Solomon BJ,
   4. Sequist LV,
   5. Gainor JF,
   6. Heist RS.

   Lung cancer. Lancet. 2021; 398: 535–54.

   OpenUrlCrossRefPubMed
2. 2.
   2. Lovly CM.

   Expanding horizons for treatment of early-stage lung cancer. N Engl J Med. 2022; 386: 2050–1.

   OpenUrlPubMed
3. 3.↵
   2. Bray F,
   3. Laversanne M,
   4. Sung H,
   5. Ferlay J,
   6. Siegel RL,
   7. Soerjomataram I, et al.

   Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229–63.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Lynch C,
   3. Pitroda SP,
   4. Weichselbaum RR.

   Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024; 25: e352–62.

   OpenUrlPubMed
5. 5.↵
   2. Bayerl F,
   3. Meiser P,
   4. Donakonda S,
   5. Hirschberger A,
   6. Lacher SB,
   7. Pedde AM, et al.

   Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity. 2023; 56: 1341–58.e11.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Wang D,
   3. Cabalag CS,
   4. Clemons NJ,
   5. DuBois RN.

   Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer. Gastroenterology. 2021; 161: 1813–29.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Siddiqui I,
   3. Schaeuble K,
   4. Chennupati V,
   5. Fuertes Marraco SA,
   6. Calderon-Copete S,
   7. Pais Ferreira D, et al.

   Intratumoral Tcf1⁺PD-1⁺CD8⁺ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019; 50: 195–211.e10.

   OpenUrlCrossRefPubMed
8. 8.
   2. Utzschneider DT,
   3. Charmoy M,
   4. Chennupati V,
   5. Pousse L,
   6. Ferreira DP,
   7. Calderon-Copete S, et al.

   T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity. 2016; 45: 415–27.

   OpenUrlCrossRefPubMed
9. 9.↵
   2. Miller BC,
   3. Sen DR,
   4. Al Abosy R,
   5. Bi K,
   6. Virkud YV,
   7. LaFleur MW, et al.

   Subsets of exhausted CD8⁺ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019; 20: 326–36.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Escobar G,
    3. Tooley K,
    4. Oliveras JP,
    5. Huang L,
    6. Cheng H,
    7. Bookstaver ML, et al.

    Tumor immunogenicity dictates reliance on TCF1 in CD8⁺ T cells for response to immunotherapy. Cancer Cell. 2023; 41: 1662–79.e7.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Khan O,
    3. Giles JR,
    4. McDonald S,
    5. Manne S,
    6. Ngiow SF,
    7. Patel KP, et al.

    TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion. Nature. 2019; 571: 211–8.

    OpenUrlCrossRefPubMed
12. 12.↵
    2. Lacher SB,
    3. Dörr J,
    4. de Almeida GP,
    5. Hönninger J,
    6. Bayerl F,
    7. Hirschberger A, et al.

    PGE₂ limits effector expansion of tumour-infiltrating stem-like CD8⁺ T cells. Nature. 2024; 629: 417–25.

    OpenUrlCrossRefPubMed